Combating Antibiotic Resistance with Microfluidic Technologies
14 Mar 2018
By 2050 antibiotic resistance could become epidemic if we continue to use antimicrobials unnecessarily. That's why researchers at the University of Southampton, UK, are working towards developing more rapid and informative clinical diagnostic tools, using microfluidic technology. These revolutionary chips identify the nature of the infection and allow clinicians to make more informed decisions on whether to prescribe antibiotics to the patient.
About the company
TwistDx
TwistDx designs and manufactures Recombinase Polymerase Amplification or RPA, a multiplexable, isothermal DNA/RNA amplification and detection technology that works amazingly fast without the need of a thermocycler. RPA is a portable alternative to PCR and is ideally suited to point-of-use molecular assays for digital, microfluidics, agriculture, veterinary and biodefense applications.
